Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazole SCHEMBL6854763 | 0.88 | LMNA (0.47) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL23957686 | 0.78 | KMT2A (0.44) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL3155897 | 0.78 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL861501 | 0.78 | LMNA (0.61) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL31516755 | 0.78 | KDM4E (0.58) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL2728318 | 0.78 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL3462062 | 0.78 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL46317 | 0.78 | KDM4E (0.58) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL22925970 | 0.78 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL29696397 | 0.78 | LMNA (0.57) | LMNAKMT2AKDM4EALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188057-A1 | NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4490148-A2 | NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| WO-2023172475-A2 | NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3072893-B1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO LTD (CN) | 2020-03-18 | — | — | EP | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| CN-1543472-A | 6-o-carbamoyl ketolide antibacterials | ����-������ҩƷ��˾ | 2004-11-03 | — | — | CN | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1343798-A1 | 6-O-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046204-A1 | 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | LMNA 1610/4885KMT2A 1404/4885KDM4E 2426/4885 |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | LMNA 4303/4885KMT2A 565/4885KDM4E 18/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | LMNA 4459/4885KMT2A 673/4885KDM4E 2/4885 |
| US-20250188057-A1 | NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | LMNA 2210/4885KMT2A 4285/4885KDM4E 3645/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | LMNA 3635/4885KMT2A 4119/4885KDM4E 4351/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | LMNA 3635/4885KMT2A 4119/4885KDM4E 4351/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | LMNA 4263/4885KMT2A 657/4885KDM4E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.